Evidence map›Paper›PMID 40486906›Full record

ArticleFrontiers in cell and developmental biology2025

A dual inhibitor of TrxR1 and XIAP induces pyroptosis in melanoma.

Yuan Wang, Xiangmei Li, Xinyue Dong, Haokun Yuan, Ruiqin Fang, Ran Zhang, Wei-Jia Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuan Wang *The School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiangmei Li *The School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xinyue Dong *The School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Haokun YuanDivision of Neonatology, Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Ruiqin FangThe School of Life Science, University of Electronic Science and Technology of China, Chengdu, China.
Ran ZhangFaculty of Science and Engineering, University of Groningen, Groningen, Netherlands.
Wei-Jia WangFujian Provincial Key Laboratory of Translational Cancer Medicine, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant melanoma ranks among the most aggressive forms of cancer, with high rates of metastasis and recurrence, as well as a poor prognosis. Consequently, an urgent need is to develop novel precision therapeutic strategies and corresponding drugs. Previous studies have shown that both X-linked inhibitor of apoptosis (XIAP) and thioredoxin reductase 1 (TrxR1) participate in the resistance of melanoma to chemotherapy-induced cell death. In this study, we designed and synthesized a series of derivatives of natural compounds derived from

Indexed as

melanomapyroptosisreactive oxygen speciesthioredoxin reductase 1 (TrxR1)X-linked inhibitor of apoptosis (XIAP)

Identifiers

PMID40486906
PMCPMC12141336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.